Nabilone Use for Acute Pain in Inflammatory Bowel Disease Patients With Chronic Opioid Use Undergoing Gastrointestinal Surgery: A Single-centered Randomized Controlled Trial

This is a clinical trial of nabilone for patients with Inflammatory Bowel Disease (IBD) who are undergoing IBD-related surgery (Any abdominal surgery lasting for more than one hour). This study would include a total of 80 patients undergoing general surgery who will have Intravenous Patient Controlled Analgesia (IVPCA) after surgery. It is the intention to randomize these patients postoperatively into 2 groups of 40 patients:
Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and nabilone as per protocol.
Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and placebo as per protocol.
The goal is two-fold. One is to demonstrate that patients will benefit from post-operative nabilone administration to achieve/maintain the opioid-sparing and pain modulation effects. Second is to demonstrate patients will benefit from the anti-inflammatory and immunomodulatory effects of nabilone to alleviate IBD symptoms and enhance recovery.

Start Date01 Dec 2023

Sponsor / Collaborator

Samuel Lunenfeld Research Institute

NCT05885685 / RecruitingPhase 4IIT

Investigating the Effects of Nabilone on Endocannabinoid Metabolism in the Human Brain

The purpose of this study is to learn about the effects of a cannabis-like substance, nabilone, on the levels of endocannabinoid enzyme fatty acid amide hydrolase (FAAH) in brain of healthy individuals. Using magnetic resonance imagine (MRI) and positron emission tomography (PET), the main questions we aim to answer are: 1) Does nabilone decrease levels of FAAH in the brain? and 2) Are changes in levels of FAAH associated with clinical response to nabilone? Participants will complete:
An in-person interview (
4 hours)
Two brain imaging scanning sessions (
11 hours)
A one week 2 mg titrated dose of nabilone
Virtual check-ins (up to
1.5 hours)

Start Date31 Oct 2023

Sponsor / Collaborator

Centre for Addiction & Mental Health

NCT05742698 / Active, not recruitingPhase 2IIT

Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia

The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.

Start Date07 Mar 2023

Sponsor / Collaborator

Douglas Mental Health University Institute

[+1]

100 Clinical Results associated with Nabilone

100 Translational Medicine associated with Nabilone

100 Patents (Medical) associated with Nabilone

324

Literatures (Medical) associated with Nabilone

01 Feb 2024·Pain management nursing : official journal of the American Society of Pain Management Nurses

Dosing of Cannabinoids Associated with an Opioid-Sparing Effect: A Systematic Review of Longitudinal Studies

Review

Author: Herrera, Norma Perez ; Zongo, Arsène ; Lunghi, Carlotta ; El-Mourad, Jihane

OBJECTIVE:

To assess cannabinoid dosing that could be associated with a reduction in opioid use.

DESIGN:

Systematic review conducted according to the PRISMA statement.

DATA SOURCES:

PubMed, Embase, Web of Science, and PsycINFO were searched up to December 10, 2022.

REVIEW/ANALYSIS METHODS:

We included randomized controlled trials (RCT) and longitudinal observational studies assessing cannabinoids effect on opioid use in patients with acute or chronic pain. Two reviewers independently assessed the studies for inclusion and extracted the data. Tetrahydrocannabinol (THC), Cannabidiol (CBD), and other cannabinoids with dosing were the exposures. Change in opioid doses and opioid discontinuation were the outcomes.

RESULTS:

Fifteen studies (including seven RCTs) were included. Eight studies (six observational and two RCTs) were conducted among patients with chronic pain including three with cancer-related pain. Seven studies involved patients with acute pain (five RCTs).In chronic non-cancer pain patients, two observational studies that assessed THC and CBD in combination (average daily dose 17mg/15mg), and one that assessed a CBD-rich extract (31.4 mg/day), showed a significant reduction in opioid use. Of the three studies conducted on patients with cancer, only the observational study that assessed nabilone (average 1.7 mg/day) showed a significant reduction in opioid use. In patients with acute pain, only two observational studies that assessed dronabinol (5mg and 5-10 mg/day for four days) showed a significant reduction in opioid use.

CONCLUSION:

The opioid-sparing effect of cannabinoids remains uncertain based on current evidence. However, attention could be paid to cannabinoid doses associated with opioid reduction in included observational studies.

01 Dec 2023·European journal of pharmacology

Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201

Article

Author: Desai, Rajeev I ; Makriyannis, Alexandros ; Ho, Thanh C ; AlKhelb, Dalal ; Georgiadis, Markos-Orestis ; Burke, Emily L ; Nikas, Spyros P ; Zvonok, Alexander ; Jiang, Shan ; Iliopoulos-Tsoutsouvas, Christos

The synthetic forms of delta-9-tetrahydrocannabinol (Δ⁹-THC), dronabinol or nabilone, have been approved to treat several indications. However, due to safety concerns their clinical utility remains limited. Consequently, there is a need for developing cannabinoid (CB) ligands that display better behavioral pharmacological profiles than Δ⁹-THC. Here, we utilized drug discrimination methods to compare the interoceptive effects of CB ligands that vary in potency, efficacy, and selectivity at the CB receptors, including two ligands, AM411 and AM4089, that show CB₁ partial agonist-like actions in vitro. Male rats were trained to discriminate 0.1 mg/kg AM2201 from saline under a fixed-ratio (FR) 10 response schedule of food reinforcement. After establishing AM2201's discriminative-stimulus effects, pretreatment tests with the CB₁ antagonist/inverse agonist rimonabant blocked AM2201's effects, whereas the peripherally-restricted antagonist AM6545 had no effect. Next, the generalization profiles of AM411 and AM4089 with CB₁ full agonists (JWH-018, CP-55,940, AM8936), partial agonist (Δ⁹-THC), and non-cannabinoids (fentanyl, atropine) were compared. The CBs either fully (AM2201, CP-55,940, JWH-018, AM8936, Δ⁹-THC) or partially (AM411, AM4089) substituted for AM2201, whereas fentanyl and atropine did not produce AM2201-like effects. All CB drugs were more potent than Δ⁹-THC and correlation analysis confirmed that the relative behavioral potencies of CBs corresponded strongly with their relative affinities at the CB₁ but not CB₂ receptors. Together, our results further demonstrate that AM411 and AM4089 exhibit better pharmacological profiles compared to Δ⁹-THC, in that they are more potent and display in vivo partial agonist-like actions that are centrally mediated via CB₁ receptors.

01 Oct 2023·Cannabis and cannabinoid research

Cannabinoids in Treating Parkinson's Disease Symptoms: A Systematic Review of Clinical Studies.

Review

Author: Panag, Sohan Singh ; Shet, Pavan ; Patel, Akash ; Varshney, Karan ; Ansari, Siraaj

Background: Parkinson's disease (PD) is a serious neurodegenerative condition impacting many individuals worldwide. There is a need for new non-invasive treatments of PD. Cannabinoids in the form of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may offer utility as treatment, and our objective was hence to conduct a systematic review regarding the clinical evidence for the efficacy and safety of cannabinoids in treating PD. Methods: Screening, data extraction, and quality assessments were all conducted by multiple reviewers, with discrepancies resolved by consensus. Results: After conducting searches in 4 different databases, 673 articles were screened. Thirteen articles were deemed eligible for inclusion in this review. It was shown that cannabis, CBD, and nabilone (a synthetic form of THC) were capable of consistently improving motor symptoms more than a placebo. All treatments improved various non-motor symptoms, particularly with cannabis improving pain intensity, and CBD improving psychiatric symptoms in a dose-dependent manner. Adverse effects were usually minor, and, in the case of CBD, rare (except at very high doses). Conclusion: Cannabinoids have been shown to safely offer important potential in treating motor symptoms in PD and some non-motor symptoms. More large-scale randomized control trials for specific forms of cannabinoid treatments are required to determine their overall efficacy.

News (Medical) associated with Nabilone

02 Feb 2024

·www.pharmaceutical-technology.com

IGC Pharma heads towards a Phase I study for Alzheimer’s disease

TGR-63, being developed to target amyloid-beta plaques, has shown preclinical potential in reducing Alzheimer’s-related anxiety. Credits: AtlasStudio/Shutterstock.com With positive preclinical data for its Alzheimer’s disease drug candidate TGR-63, IGC Pharma has announced that it plans to advance this small molecule into early clinical development in the course of 2024. TGR-63 is an amyloid beta peptide-targeting drug designed to decrease plaque aggregation by preventing the misfolding and aggregation of amyloid-beta peptides. In the preclinical mouse models designed to assess behavioural responses in transgenic mice, subjects treated with TGR-63 demonstrated statistically significant reductions (43%) in overall movement as determined by an Open-Field behavioural test. As per the 1 February press release, the data reinforces “its [TGR-63] potential as a promising treatment” for reducing levels of anxiety and improving emotional wellbeing. The Timonium, Maryland-based pharmaceutical company is also actively evaluating its cannabinoid-based lead candidate IGC-AD1 as a treatment for Alzheimer’s dementia-associated agitation in a Phase IIb study (NCT05543681). In December 2023, the company announced a partnership with Los Andes University’s Center for Research and Training in Artificial Intelligence (CINFONIA) to incorporate generative AI analyses into the Phase II trial. IGC Pharma is in the process of training algorithms with the goal of identifying clues for reducing misdiagnoses and false negatives, which is important as misdiagnoses and false negatives tend to be high in the Alzheimer’s indication, CEO Ram Mukunda told Pharmaceutical Technology . By addressing these issues, the company aims to improve trial success rates and ultimately accelerate the development and delivery of economic, effective treatments for Alzheimer’s patients, he adds. See Also: Sanofi backs development of Graviton’s treatments for serious diseases Tyra Biosciences’ TYRA-300 gains FDA rare paediatric disease status Despite making headway with its lead pipeline candidate, IGC Pharma has faced difficulties in trial enrolment and finances for IGC-AD1 due to its active ingredient being the psychoactive substance tetrahydrocannabinol (THC). THC is federally regulated and therefore the study or use of it requires a special permit as it is not covered by a DEA license that could be used for a drug like morphine, Mukunda explained. While Otsuka Pharmaceuticals’ Rexulti (brexpiprazole), an atypical antipsychotic, is the only FDA-approved medication for Alzheimer’s-associated agitation, other small molecules are in clinical development for Alzheimer’s agitation. Otsuka is evaluating AVP-786, a dextromethorphan/quinidine combination treatment for Alzheimer’s agitation, in multiple global Phase III studies. Similar to IGC Pharma, Sunnybrook Health Sciences Centre is also conducting a Phase III trial (NCT04516057) of cannabinoid based Nabilone for the treatment of agitation. GlobalData forecasts Rexulti to bring $3.9 billion in sales in 2028. GlobalData is the parent company of Pharmaceutical Technology .

Phase 1Phase 2Clinical ResultPhase 3Drug Approval

28 Nov 2023

·www.outsourcing-pharma.com

Interview: DSM-Firmenich innovates with cannabidiol formulations

In a conversation at CPHI Barcelona last week, global market development manager Athanasia Kanli and manager marketing communication Céline Zuber explained how the company is tackling this mission. Some of the substances derived from the cannabis plant are famous for their mind-altering effects - like tetrahydrocannabinol (THC), whose recreational use is illegal in many countries. However, the medical applications of cannabis, particularly those linked to active ingredients in the plant, are gaining increasing interest. For example, the US Food and Drug Administration (FDA) has greenlit synthetic cannabis-related drug products including dronabinol and nabilone. The agency also made history in 2018 by approving Epidiolex, the first treatment based on purified CBD derived from marijuana. Epidiolex, which is marketed for two rare forms of epilepsy, consists of an oral solution of the non-psychoactive ingredient CBD. Zuber explained that the emerging CBD market is “developing in a favorable direction” at the moment and there are myriad potential applications, especially in mental health conditions and pain management. Nonetheless, she cautioned that there are multiple challenges for biotech companies developing CBD-based treatments such as difficulties in formulating the compound into solid oral dosage forms, the low bioavailability of the active ingredient, and complex regulations across the globe. In tandem with partner company Brains Bioceutical, dsm-firmenich is developing a platform to guide biotech and pharma customers through the complex development and manufacturing of their CBD treatment candidate treatments. “There’s the product but there's also the regulatory expertise, being able to design clinical trials, all the way to scanning the right pathway to enter the market,” said Zuber. “We can facilitate all of that together with Brains Bioceutical.” googletag.cmd.push(function () { googletag.display('text-ad1'); }); Teaming up with Bod Science One CBD innovator working with dsm-firmenich is the Australian company Bod Science. The companies joined forces last month to fuel the development of what could become the world’s first CBD-based treatment for insomnia. According to the release , Bod Science is soon due to publish full results from a phase 2b trial of the treatment and deploy dsm-firmenich and Brains Bioceutical’s manufacturing and development expertise to fuel the next stage of commercialization. Prior to the partnership, Kanli saw Bod Science as a forward-looking company with a strong scientific perspective on the drug development process. “We were in conversations for a while and then at some point, we got to the conclusion that this was the right partnership for both of us,” she said. In addition to manufacturing support, dsm-firmenich and Bod Science plan to collaborate in at least two therapeutic areas and grow the partnership towards new formulations and new formats, said Kanli. She added that more information would be released in the coming months. Solid progress One obstacle for formulating CBD is that the compound is hard to dissolve in water and is typically delivered in oil or alcohol as soft-gel capsules, a liquid solution, sublingual drops, or an oromucosal spray. In the case of Epidiolex, CBD is mixed in oil and delivered orally via a measuring syringe. “If you have to administer [CBD] to a child with epilepsy, you might have to give them a tablespoon of oil twice a day,” said Kanli. “I don't want to try to give that to a three-year-old; it's not the most pleasant thing you can do.” To tackle this challenge, dsm-firmenich is developing a solid CBD formulation that could be delivered in a range of forms including a chewable pill or powder. Compared with current formulations, this formulation could be easier for patients to receive, improve absorption of CBD through the gut and reduce side effects. “The liver is going to be better, the stomach is going to be better, and there will be fewer drug-drug interactions,” said Kanli, adding that this could also improve patient compliance with dosage regimes. The company plans to trial the novel formulation in humans next year. While there are other solid CBD formulations in development at other companies, dsm-firmenich was the first to demonstrate improved CBD bioavailability in the solid form, Kanli said. As dsm-firmenich continues to design and develop new formulations, its mission has become easier with the merger that formed dsm-firmenich this year. The DSM side has all of the formulation expertise whereas the Firmenich side – specializing in flavorings and fragrances – can make CBD products more appealing to patients. “Let's assume you have a film under the tongue: you want it to taste good, right?” said Kanli. “It's really exciting.”

Phase 2Drug Approval

06 Nov 2023

·www.prnewswire.com

The Pharmaceutical Cannabis Report 2023: Global Sales Projected to Grow to US$1.37 Billion by 2027

DUBLIN, Nov. 6, 2023 /PRNewswire/ -- The "Pharmaceutical Cannabis Report: 3rd Edition" report has been added to ResearchAndMarkets.com's offering. The burgeoning use of cannabinoids for medical treatment presents both immense opportunities and challenges, propelled by promising research on the endocannabinoid system yet hampered by fluctuating regulations. The present market, predominantly driven by non-traditional medical prescriptions, is witnessing a shift towards more precise formulations, especially in Europe. The United States, on the other hand, continues to see dominance in sales of medical flower and vaporized products among unapproved medicines. However, the pharmaceutical cannabinoid, Epidiolex, stands out as a success story, illustrating the potential within this space, generating over €430 million in sales in 2020 and aiding over 20,000 patients, despite the hurdles faced by its producer, GW Pharmaceuticals, over a span of 20 years to achieve substantial sales. The market for cannabinoid pharmaceuticals is poised for growth with an estimated value of nearly €900 million as of 2021, expected to double by 2025. This growth trajectory is likely to be sustained or even accelerated with the approval of new cannabinoid therapeutics or the expansion of existing medicines into new regions or conditions. The industry is currently bustling with at least 30 late-stage clinical trials for cannabinoid therapeutics and burgeoning research on minor cannabinoids like Cannabigerol (CBG) and Cannabichromene (CBC). Additionally, the market is beginning to mature for synthetic cannabinoids, with commercial production of Tetrahydrocannabinol (THC) and Cannabidiol (CBD) through biosynthetic processes. The evolving patent landscape and the upcoming expiration of market exclusivity on Epidiolex signal potential legal battles and the entrance of generic versions, respectively. As the market gradually transitions towards precise cannabinoid formulations over the next decade, propelled further by the liberalization of adult-use cannabis, the medical cannabinoid sector is on the cusp of unveiling a plethora of new therapeutics globally, underscoring a promising yet competitive future for operators in this space. This report gives a clear and detailed account of all activity involving cannabis and cannabinoids in the landscape of pharmaceutical medicine, at a global level. The main topics covered include an analysis of the relevant landscape in clinical trials, patents and innovation. As well as this, a market-sizing forecast for the global pharmaceutical cannabis industry for the period 2023-2027 is presented, with accompanying commentary, and a short analysis of the recent M&A activity and research funding activity relevant to the sector is included. Discussion of the topics covered is informed and supported by extensive data produced during research for the report. Throughout the main sections, this data is visualised in order to provide evidence and clarification to analysis. Whenever possible, context is provided to explain the factors that have brought about the current circumstances in the relevant sphere of activity, and what constraints face those operating within it. Recent developments and trends are highlighted in order to draw attention to the most significant dynamics in each area. Key Findings Global sales within the pharmaceutical cannabis industry are estimated to reach approximately US$1.11 billion in 2023, with projected growth to US$1.37 billion by 2027. Epidiolex (Epidyolex in Europe) is the dominant player in the market, with an estimated market share of around 76% projected for 2023. In the pharmaceutical cannabis industry, the only drug to generate significant sales (of approximately €160 million annually) apart from Epidiolex and Sativex is dronabinol. There is growing interest in research around non-cannabinoid compounds targeting the endocannabinoid system. Jazz Pharmaceuticals dominated the patent landscape for the medical application of cannabinoids, and has a patent portfolio which dwarfs that of any other company involved in patenting activity around the medical application of cannabinoids. CBD and THC are still seeing the majority of patent activity versus other cannabinoids, as they have historically. A large amount of activity is also focused on cannabinoids and compounds that are closely related to these cannabinoids, for example CBDV, THCV, CBDA, and relevant prodrugs and analogues. There is a wide variation in the costs associated with each stage of the clinical trials process, but even at the lowest end, bringing a medicine to the market is going to cost US$20 million or more. Pharmaceutical cannabis sales are concentrated in two regions globally - North America and Europe. Within these regions, sales are not evenly distributed but are concentrated in key markets. What's Included: A digital copy of the report which includes an assessment of the market size within the pharmaceutical cannabis industry, which primarily consists of three cannabinoid treatments: Epidiolex, dronabinol, and Sativex. The impact of Syndros, Marinol, nabilone and Cesamet/Canemes on the overall figures is of little significance - collectively, these medications are projected to contribute less than US$3 million in 2023, representing less than 0.3% of the global sales. For this reason, they have not been included in the charts in this section For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Nabilone

External Link

KEGG	Wiki	ATC	Drug Bank
D05099	Nabilone	A04AD11	DB00486

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chemotherapy-induced nausea and vomiting	US	Bausch Health US LLC	26 Dec 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Agitation	Phase 2	CA	Douglas Mental Health University Institute	07 Mar 2023
Aphasia, Primary Progressive	Phase 2	CA	Douglas Mental Health University Institute	07 Mar 2023
Frontotemporal Dementia	Phase 2	CA	Douglas Mental Health University Institute	07 Mar 2023
Neuralgia	Phase 2	CA	Valeant Canada Ltd.	01 Jan 2009
Phantom Limb	Phase 2	CA	Valeant Canada Ltd.	01 Jan 2009
Fibromyalgia	Phase 2	CA	Valeant Canada Ltd.	01 Apr 2006
Chronic Pain	Phase 2	CA	Bausch Health Americas, Inc.	01 Dec 2005
Sleep Initiation and Maintenance Disorders	Phase 2	CA	Bausch Health Americas, Inc.	01 Dec 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03773796 (CTgov)	Phase 3	Parkinson Disease	22	Nabilone 0.25 mg	mgkxsqvdxp(ulhetpneil) = jskoiraqcc oiznpkkoaq (ylvkrdfdmf, xwhaalswra - ojijvtkdwv) View more	-	02 Mar 2021
NCT03769896 (CTgov)	Phase 2	Parkinson Disease	48	Nabilone 0.25 mg (Treatment Group)	ipiodxbwyz(ilghvbsfbb) = hyzolufwig oxflwioese (qzcfglahjz, qzvhbzhuxg - zexebgufch) View more	-	02 Mar 2021
				placebo (Placebo Group)	ipiodxbwyz(ilghvbsfbb) = dzczogjgcl oxflwioese (qzcfglahjz, woovwtbjgv - jbbppbetoe) View more
NCT03251326 (CTgov)	Phase 1/2	Stress Disorders, Post-Traumatic \| Marijuana Abuse \| Wounds and Injuries	4	Plac+Nab (Active Nab > Plac Prop > Plac Cann)	hcpimfwisj(nknptsogbr) = mokrjopjgh oijixcuhjx (vlzjiimdgt, lfngnmaeca - talivlqshv) View more	-	12 Oct 2020
				Nab (Plac Nab > Act Prop > Plac Cann)	hcpimfwisj(nknptsogbr) = zdyyudwmxf oijixcuhjx (vlzjiimdgt, xofruqlpto - rsgsbxcvtg) View more
MDS2020	Phase 2	-	48	Nabilone	mpvhwxgbht(wptvwohwhc) = Similar proportions of patients in each group had adverse events (placebo-group: 42%; nabilone: 32% of the group) usxjgxnzqg (ntjzktyykw ) View more	Positive	12 Sep 2020
				Placebo
NCT03769896 (Pubmed \| Ann Neurol)	Phase 2	Parkinson Disease	47	Nabilone	reliaqtoat(bjywbvvzjf) = juwmsfyxpj lsvwopmqwk (qphwxayyns )	Positive	05 Aug 2020
				Placebo	reliaqtoat(bjywbvvzjf) = nxpkthqpav lsvwopmqwk (qphwxayyns )
NCT02802540 (WCLC2018)	Phase 2/3	Lung Cancer	47	Nabilone	nlpazqrkii(dehfyolrll) = had a significantly improvements olmsunejrh (glxtirkmkz )	-	24 Sep 2018
NCT02802540 (Pubmed \| Support Care Cancer)	Phase 2/3	Lung Cancer	65	Nabilone	enywynnbux(ehxengairk) = bssrwkorfi mvoozbcmfh (iowwkbeoeq ) View more	Positive	01 Sep 2018
NCT01347762 (CTgov)	Phase 2/3	Marijuana Use \| Cannabis withdrawal	84	Nabilone (Nabilone Titrated 2 mg Daily (Phase 1))	wsyjcqivif(pccgqhvbkz) = knqkwfoatl iqcwfzaucg (ttaozpwrbq, yygqfuskzn - eteiiqpbwp) View more	-	01 Jun 2018
				Placebo (Placebo (Phase 1))	wsyjcqivif(pccgqhvbkz) = viilahpznz iqcwfzaucg (ttaozpwrbq, bqampwmylu - eostqtmrgy) View more
NCT02115529 (Pubmed \| Can J Anaesth)	Phase 2	Postoperative Nausea and Vomiting	340	Nabilone 0.5 mg	dsniyqmqrf(qcxldtalvk) = iqhlrcusqh fxxwrguqzj (ycsdnmbzdf )	Negative	01 Apr 2017
				Placebo	dsniyqmqrf(qcxldtalvk) = msmrcmqots fxxwrguqzj (ycsdnmbzdf )
NCT03422861 (Pubmed \| Pain)	Not Applicable	Diabetic peripheral neuropathic pain Adjuvant	-	Nabilone	tcyyfdkofy(spgwvyepxu) = led to discontinuation in 2/37 subjects during single-blind nabilone treatment tdmpxebdhu (iisiuyuqed ) View more	Positive	01 Oct 2012
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis